Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds bacterium or component thereof or substance produced...
Reexamination Certificate
2005-12-27
2005-12-27
Housel, James C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds bacterium or component thereof or substance produced...
C424S130100, C424S133100, C424S164100, C424S165100, C424S237100, C424S243100, C435S007330, C530S387100, C530S388400
Reexamination Certificate
active
06979446
ABSTRACT:
Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein fromStaphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such asStaphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability ofS. aureusClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.
REFERENCES:
patent: 4795803 (1989-01-01), Lindberg et al.
patent: 5240833 (1993-08-01), Nudelman et al.
patent: 5326696 (1994-07-01), Chang
patent: 5648240 (1997-07-01), Hook et al.
patent: 5718899 (1998-02-01), Gristina et al.
patent: 6008341 (1999-12-01), Foster et al.
patent: 6177084 (2001-01-01), Foster et al.
patent: 6288214 (2001-09-01), Hook et al.
patent: 0 520 499 (1992-12-01), None
patent: WO 94/05690 (1994-03-01), None
patent: WO 94/10332 (1994-05-01), None
patent: WO 97/43314 (1997-11-01), None
patent: WO 99/24467 (1999-05-01), None
patent: WO 00/12132 (2000-03-01), None
patent: WO 00/26671 (2000-05-01), None
patent: WO 0064925 (2000-11-01), None
Hall et al., Infection and Immunity, vol. 17 No. 12, pp. 6864-6870 (Dec. 2003).
Ichiman et al., Canadian Journal of Microbiology, vol. 37, pp. 404-407 (1991).
Patti et al., “Mscramm-Mediated Adherence of Microorganisms to Host Tissues”, Ann. Rev. Microbiol, 1994, 48:585-617.
Foster et al., “Surface-associated proteins ofStaphylococcus aureus: Their possible roles in virulence”, FEMS Microbiology Letters 118 (1994) 199-206.
Chhatwal et al., “Interaction between fibronectin and purified staphylococcal clumping factor”, FEMS Microbiology Letters 44 (1987) 147-151.
McCrae et al., “Molecular Aspects of Host-Pathogen Interaction”, 55thSymposium of the Society for General Microbiology, Heriot-Watt University, Edinburgh, Mar. 1997.
McDevitt et al., “Genetic Evidence that Bound Coagulase ofStaphylococcus aureusIs Not Clumping Factor”, Infection and Immunity, Apr. 1992, vol. 60, No. 4, pp. 1514-1523.
Vaudaux et al., “Host Factors Selectively Increase Staphylococcal Adherence on Inserted Catheters: A Role for Fibronectin and Fibrinogen or Fibrin”, The Journal of Infectious Diseases, vol. 160, No. 5, Nov. 1989.
Vaudaux et al., “Fibronectin Is More Active than Fibrin or Fibrinogen in PromotingStaphylococcus aureusAdherence to Inserted Intravascular Catheters”, The Journal of Infectious Diseases, 1993, 167:633-41.
Boden et al., “Fibrinogen-Binding Protein/Clumping Factor fromStaphylococcus aureus”, Infection and Immunity, Aug. 1989, vol. 57, pp. 2358-2363.
Boden et al., “Cloning and characterization of a gene for a 19 kDa fibrinogen binding protein fromStaphylococcus aureus”, Molecular Microbiology (1994) 12(4), pp. 599-606.
McDevitt et al., “Molecular characterization of the clumping factor (fibrinogen receptor) ofStaphylococcus aureus”, Molecular Microbiology (1994) 11(2), pp. 237-248.
O'Connell et al., “The Fibrinogen-binding MSCRAMM (Clumping Factor) ofStaphylococcus aureusHas a Ca2+-dependent Inhibitory Site”, Biological Chemistry, vol. 273, No. 12, Issue of Mar. 20, 1998, pp. 6821-6829.
McDevitt et al., “Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) ofStaphylococcus aureus”, Molecular Microbiology (1995), 18(5), pp. 885-907.
Tillman et al., “Both IgM and IgG Anti-DNA Antibodies Are the Products of Clonally Selective B Cell Stimulation in (NZB×NZW)F1 Mice”, J. Ex. Med., The Rockefeller University Press, vol. 176, Sep. 1992, pp. 761-779.
Klobeck et al., Nucleic Acids Research “Subgroup IV of human immunoglobulin K light chains is encoded by a single germline gene”, IRL Press Limited, Oxford, England, vol. 13, No. 18, 1985, pp. 6515-6529.
Monestier et al., “Ig light chain V region (ASWA1)—mouse (fragment )”, S38559, Submitted to the EMBL Data Library Sep., 1993.
McDovitt et al. “Characterization of the interaction between theStaphylococcus aureusclumping factor (CLFA) and fibrinogen”, European Journal of Biochemistry 247 (1), 1997.
Bayer et al., “Therapeutic Administration of an Anti-Clumping Factor (ClfA) Hyperimmune Globulin (SA-IVIG-Reduces the Duration . . . ”, Abstracts of the General Meeting of the American Society of Microbiology, vol. 101, 2001, p. 29.
Hartford et al., “The dipeptide repeat region of the fibrinogen-binding protein (clumping factor) is required . . . ” Molecular Microbiology (1997) 25(6), pp. 1065-1076.
Hartford et al., “Identification of Residues in theStaphylococcus aureusFibrinogen-binding MSCRAMM Clumping Factor A (ClfA) . . . ” The Journal of Biological Chemistry, vol. 276, No. 4, Issue of Jan. 26, 2001, pp. 2466-2472.
Domanski Paul
Hall Andrea
Hutchins Jeff T.
Patel Pratiksha
Patti Joseph M.
Housel James C.
Inhibitex, Inc.
Lucas Zachariah
Schulman B. Aaron
Stites & Harbison PLLC
LandOfFree
Monoclonal antibodies to the ClfA protein and method of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies to the ClfA protein and method of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies to the ClfA protein and method of use... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3514345